TrialJAMA oncology2018

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.

Karen A Autio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.